Next Clinical Trial Of VaxGen's Anthrax Vaccine Delayed
Sat, 04 Nov 2006 08:00 AM EST
... VaxGen, Inc. (Pink Sheets: VXGN.PK) announced today that it has received a clinical hold notification from the Food and Drug Administration (FDA) that will postpone the initiation of the company's second Phase II trial for its investigational anthrax vaccine, rPA102. [click link for full article] ...
Related Topics
- Clinical Trials
- Anthrax
- Anthrax Vaccine
- Vaccine
- Vaccine Side Effects
- Polio Vaccine & Cancer
- Polio Vaccine
- Polio Vaccine & Origin of HIV/AIDS
- Pharmacology
- MMR Vaccine & (Asceptic) Meningitis
- Trastuzumab
- Smallpox Vaccine
- Psychopharmacology
- Chickenpox Vaccine
- Hepatitis A Vaccine
- Hepatitis A and Hepatitis B Vaccine
- Tarceva
- Hepatitis B Vaccine
- Pneumococcal Vaccine
- Epidemiology & Prevention of Vaccine-Preventable Diseases

Not Signed In -


